【painted turtle laying eggs in yard】Gilead Sciences Could Be the First to Beat the Coronavirus
Thepainted turtle laying eggs in yard coronavirus’ grip on the market continues. Since the beginning of February, the S&P 500 has shed 8.5% of its value, a reflection of the effect the outbreak is having on the global economy. Amidst the bloodbath, one specific group of stocks is holding up. These are the drug companies those infected, the public at large and investors are hoping can halt the virus from spreading any further. Gilead Sciences (
GILD
) is among those leading the search for a treatment and is currently being rewarded by the market. In contrast to the broader market, GILD stock is up 23% year-to-date.
Remdesivir, one of the company’s existing drugs which was previously tested as a possible treatment for Ebola, is being tested as a potential treatment for COVID-19.
Gilead has initiated two Phase III studies in China, one in severe patients and one in patients with moderate symptoms. The trials will have short endpoints (14 days), with the possibility of data readouts in April.
In addition to the coronavirus developments, Gilead also recently announced it will acquire immuno-oncology specialist Forty Seven, in a deal worth $4.9 billion.
While Jefferies’
Michael Yee
remains positive on Gilead’s prospects, the 4-star analyst tempers expectations of the drug’s financial impact. “We applaud the efforts - but reiterate while this is fundamentally positive, the financial implications are modest (pricing, one-time use, no tail). Also, in our discussions, while GILD is hopeful on the efficacy, they caution CV should not be a key driver to valuation, since it is mostly humanitarian and unlikely to drive any material benefits. In our math, even at a $1,000-5,000 price x 500,000 estimate points, this is $500 million-$2 billion-plus but GILD has been known to give away aid to regions at cost,” said Yee
Yee reiterated a Buy on Gilead, along with a price target of $76. Gilead’s recent surge means the figure currently implies possible downside of 5.26%. (To watch Yee’s track record,
click here
)
Maxim Group’s
Jason McCarthy
is also skeptical of the drug’s ability to drive profit.
The analyst noted, “The coronavirus threat is real, and it should be a concern to the public-no question. However, from an investing perspective, we view remdesivir as a relatively modest opportunity at best for Gilead, and not a growth driver. That said, we are not at all minimizing Gilead's efforts to rapidly advance remdesivir to see if they have a drug for coronavirus that could save lives. Actually, the company's efforts are impressive to say the least. We are looking at it purely through the lens of the value proposition and the growth prospects of the company; fundamentals vs. hype.”
Story continues
Accordingly, McCarthy remains on the fence and maintains his Hold rating. The analyst currently has no price target. (To watch McCarthy’s track record,
click here
)
The Street’s take on the virus fighter is currently split almost evenly down the middle. 9 Buys, 9 Holds and 1 Sell add up to a Moderate Buy consensus rating. The average price target is $75.94 and implies that the analysts see the stock dropping 5.34% from current levels. (
See Gilead stock-price forecast on TipRanks
)
To find good ideas for stocks trading at attractive valuations, visit TipRanks’
Best Stocks to Buy
, a newly launched tool that unites all of TipRanks’ equity insights.
View comments
-
Earnings Outlook for Manitowoc CoSony Announces the α77II (Alpha 77 Mark II) Translucent Mirror DSLR CameraSan Bernardino shooting lawsuits vs Facebook, Google, Twitter dismissed‘Stranger Things’ Renewed for Third Season at NetflixUnum (UNM) Q1 Earnings and Revenues Lag EstimatesAmazon Web Services brought in more money than McDonald’s in 2018Liberty Broadband Corp (LBRDA) Q4 2018 Earnings Conference Call TranscriptCopart (CPRT) Gains From Auction Locations Despite High CostsIRS offers new relief options to help with tax bills during coronavirus pandemicBRIEF-Lens Technology's Unit Receives Government Supporting Fund Of 109.46 Mln Yuan
下一篇:Exclusive: Germany ready to nationalise airline Condor - sources
- ·Moving Average Crossover Alert: Tenable
- ·Dubai 2019 budget halts spending growth as revenue rise slows
- ·What Should Investors Know About Ascott Residence Trust’s (SGX:A68U) Future?
- ·Senate GOP Adds 2 Women to Powerful Judiciary Committee, Report Says
- ·iRhythm Technologies, Inc. Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
- ·Cabinet approves merger of three state-owned banks
- ·Congress leaders invited to White House for border briefing
- ·Why General Electric Stock Popped 8% Today
- ·Realogy Holdings Corp.'s (NYSE:RLGY) Intrinsic Value Is Potentially 88% Above Its Share Price
- ·Florida's Highway Safety Report Finds Crashes Continue to Decrease at Red-Light Safety Camera Intersections
- ·How Much Are Uni-Select Inc. (TSE:UNS) Insiders Spending On Buying Shares?
- ·Is Primoris Services Corporation (NASDAQ:PRIM) Expensive For A Reason? A Look At The Intrinsic Value
- ·4 Top Momentum Stocks Powered by Driehaus Strategy
- ·Largest Mutual Funds Give Loyal Shareholders Unwanted Capital Gains Distributions
- ·Does STI India Limited (NSE:STINDIA) Have A Volatile Share Price?
- ·China to execute driver who killed passenger of ride-hailing firm Didi
- ·Global Compression Garments Market – Analysis By Product Type, By End User, By Region, By Country (2020 Edition): Market Insights, COVID-19 Impact, Competition and Forecast (2020-2025)
- ·Lil Wayne Rocks, but Tyler, the Creator Steals the Show at Gov Ball Day One
- ·A More Inclusive Language
- ·Nigeria's Kaduna refinery expected to resume by mid-April - NNPC
- ·The Downsides of 401(k)s That You’ve Never Heard Of
- ·Why Vita Life Sciences Limited (ASX:VLS) Looks Like A Quality Company
- ·Weekly Outlook: December 3 - 7
- ·A Close Look At Astral Poly Technik Limited’s (NSE:ASTRAL) 22% ROCE
- ·Ukraine prime minister ousted, president seeks 'new brains'
- ·European VC trends in 9 charts
- ·Waiting for passengers, American puts Boeing Max in the air
- ·‘The Biggest Loser’ Has A Grand Prize Winner In Season Finale
- ·10 Top Stock Picks From the Street’s Best Analysts
- ·The Top 10 Cryptocurrencies Aren’t The Most Actively Developed
- ·Why the Earnings Surprise Streak Could Continue for Dick's (DKS)
- ·'Rip-roaring reasonableness': Stephen Colbert, more late night TV hosts weigh in on SOTU
- ·PG&E must deal with problem that bankruptcy won't end: fires
- ·Apple’s iPhone Warning Comes Years Too Late
- ·Avista (AVA) Misses Q3 Earnings and Revenue Estimates
- ·Nexans : Information on share capital and voting rights - DECEMBER 2018